


Catalyst-Controlled Chemoselective Arylation of 2-Aminobenzimidazoles**

Satoshi Ueda and Stephen L. Buchwald*

Transition-metal-catalyzed heteroatom arylation reactions are emerging as valuable tools in organic synthesis, fuelled by the identification of more efficient catalyst systems with increased substrate scopes.^[1] The synthetic utility of these transformations is increased if catalysts are both highly reactive and selective. This is particularly important for substrates with multiple heteroatom sites capable of undergoing reaction. Furthermore, the development of complementary sets of catalysts or conditions for the selective arylation of substrates possessing multiple nucleophilic sites enables the rapid, protecting group-free generation of molecular complexity with minimal synthetic manipulations. In this context, we have developed sets of procedures for the Pd- and Cu-catalyzed chemoselective arylation of aminobenzamides,^[2a] 5-aminoindole,^[2a] 4-(2-aminoethyl)aniline,^[2a] amino alcohols,^[2b] oxindoles,^[2c] and aminophenols.^[2d]

During our work on the N-arylation of nitrogen-containing heterocycles,^[3] we became interested in the use of 2-aminobenzimidazoles as potential substrates for chemoselective N-arylation reactions. Both N¹-aryl-2-aminobenzimidazoles and 2-arylaminobenzimidazoles are found in a variety of medicinally important compounds including integrin $\alpha_4\beta_1$ antagonists,^[4] mTOR inhibitors,^[5] aurora kinase inhibitors,^[6] Tie-2 kinase inhibitors,^[7] Ca channel blockers,^[8] and CXCR2 antagonists.^[9] Thus, the selective syntheses of both of these isomers from a common core structure represent attractive alternatives to other previously employed routes^[10,11] and could provide rapid access to a diverse array of potentially bioactive 2-aminobenzimidazole derivatives (Scheme 1).

While the efficient Cu-^[12] and Pd-catalyzed^[13] N¹-arylations of some benzimidazole derivatives with aryl halides have been described, the chemoselective N-arylation of unprotected 2-aminobenzimidazoles with aryl halides has received little attention.^[14–16] Potential challenges of such an approach include the formation of regioisomers and/or poly-arylated products due to the presence of three adjacent nucleophilic nitrogens (N¹, N³ and C²-amino group), as well as the tautomeric nature of 2-aminobenzimidazoles. Herein, we



Scheme 1. Chemoselective arylation of 2-aminobenzimidazole.

report the successful development of an orthogonal set of Pd- and Cu-catalyzed chemoselective conditions for the N-arylation of unprotected 2-aminobenzimidazoles and related aminoazoles.

We initiated our investigation by examining the Pd-catalyzed coupling of 2-aminobenzimidazole and bromobenzene (Table 1). With [Pd₂(dba)₃] (0.1 mol %; dba = dibenzylideneacetone), **L1** (0.2 mol %), and K₃PO₄, the N-arylation went smoothly to give 2-anilinobenzimidazole **1a** in 92 % yield and without formation of regioisomer **1b** or poly-arylated products (entry 1). The use of other biaryl phosphine ligands (**L2–L4**) provided low yields of product under these conditions. Replacing K₃PO₄ with other bases also resulted in lower yield of the product (entries 5 and 6).

Turning our attention to finding conditions for the selective formation of the the N¹-arylated product (**2a**), we found that reactions with a Cu-catalyst system (iodobenzene/bromobenzene, CuI, **L5**,^[17] and Cs₂CO₃) were completely chemoselective, providing no trace either of regioisomer **1a** or of any poly-arylated products (entries 7 and 8). The use of other ligands (**L6–L8**) and bases did not alter this chemoselectivity, but rather gave lower yields of **1b** (entries 9–13). Thus, complete selectivity and complementarity can be achieved by using Pd- and Cu-based catalyst systems.

We next explored the scope of the Pd-catalyzed selective N-arylation of aminoazoles, and found that a variety of 2-aminobenzimidazoles and 2-aminoimidazole could be coupled chemoselectively with both electron-rich and electron-poor aryl halides, as well as with an *ortho*-substituted aryl halide (Table 2, **1b–1h**).^[18] For 3-amino-5-alkylpyrazoles the primary amino groups were also selectively and efficiently arylated by using 0.2–0.5 mol % catalyst. Though the selective Pd-catalyzed N-arylation of 3-aminopyrazoles has been previously reported, relatively high catalyst loadings (5 mol % Pd and 10 mol % **L4**) and the use of a strong base (NaOtBu) were required.^[13a]


The scope of the Cu-catalyzed N¹-selective arylation was also investigated (Table 3). Reactions of 2-aminobenzimidazoles and 2-aminoimidazole with a variety of functionalized aryl iodides gave N¹-arylated products **2b–2f** and **2i** selec-

[*] Dr. S. Ueda, Prof. Dr. S. L. Buchwald
Department of Chemistry, Room 18-490
Massachusetts Institute of Technology
Cambridge MA 02139 (USA)
E-mail: sbuchwal@mit.edu


[**] This work is supported by National Institutes of Health (GM58160). S.U. thanks the Japan Society for the Promotion of Sciences (JSPS) for a Postdoctoral Fellowship for Research Abroad. We thank Dr. Meredith A. McGowan for help with preparation of this manuscript.

Supporting information for this article is available on the WWW under <http://dx.doi.org/10.1002/anie.201204710>.

Table 1: Reaction optimization.^[a]


					
Entry	Metal source (mol %)	Ligand (mol %)	X	Base (1.5 equiv)	Yield [%]
1	[Pd ₂ (dba) ₃] (0.1)	L1 (0.2)	Br	K ₃ PO ₄	1a /92
2	[Pd ₂ (dba) ₃] (0.1)	L2 (0.2)	Br	K ₃ PO ₄	1a / < 5
3	[Pd ₂ (dba) ₃] (0.1)	L3 (0.2)	Br	K ₃ PO ₄	1a /23
4	[Pd ₂ (dba) ₃] (0.1)	L4 (0.2)	Br	K ₃ PO ₄	1a / < 5
5	[Pd ₂ (dba) ₃] (0.1)	L1 (0.2)	Br	Cs ₂ CO ₃	1a /14
6	[Pd ₂ (dba) ₃] (0.1)	L1 (0.2)	Br	NaOtBu	1a / < 5
7	CuI (10)	L5 (15)	I	Cs ₂ CO ₃	2a /89
8 ^[b]	CuI (10)	L5 (15)	Br	Cs ₂ CO ₃	2a /70
9	CuI (10)	L6 (15)	I	Cs ₂ CO ₃	2a /10
10	CuI (10)	L7 (15)	I	Cs ₂ CO ₃	2a /45
11	CuI (10)	L8 (15)	I	Cs ₂ CO ₃	2a / < 5
12	CuI (10)	L5 (15)	I	K ₂ CO ₃	2a /45
13	CuI (10)	L5 (15)	I	K ₃ PO ₄	2a /39

[a] Conditions for entries 1–6: PhBr (1 mmol), 2-aminobenzimidazole (1.1 mmol), base (1.5 mmol), [Pd₂(dba)₃] (0.1 mol %), ligand (0.2 mol %), *t*BuOH (1.5 mL), 120 °C, 5 h. Conditions for entries 7–13: PhI or PhBr (1 mmol), 2-aminobenzimidazole (1.1 mmol), base (1.5 mmol), CuI (10 mol %), ligand (15 mol %), *t*BuOH (1.5 mL), 90 °C, 16 h. [b] Reaction was performed at 120 °C.



tively and in good yields. The N-arylation of unsymmetrical 2-amino-4-methylbenzimidazole reacted at the less sterically hindered N¹-position to provide **2g**. Both electron-rich (**2e**, **2g**) and electron-deficient aryl halides reacted smoothly to give products in high yield. Lastly, reactions of 2-alkylamino-benzimidazoles gave N¹-arylated products **2j** and **2k** in good yields. Not surprisingly, the process showed good functional-group compatibility.

Having established a complementary set of Pd- and Cu-catalyzed chemoselective arylation methods, we sought to apply our methods to selective two-step syntheses of diarylaminoazoles from unprotected aminoazoles by using sequential Pd- and Cu-catalyzed reactions (or vice versa). Parent 2-aminobenzimidazole could be selectively arylated by an initial Pd-catalyzed N-arylation of 2-aminobenzimidazole, followed by a subsequent Cu-catalyzed arylation to give **3** (Scheme 2). Diarylated 3-aminoindazole **4** was prepared by

Table 2: Scope of the Pd-catalyzed N-arylation.^[a]


[a] Aryl halide (1 mmol), aminoazole (1.1 mmol), K₃PO₄ (1.5 mmol), [Pd₂(dba)₃] (0.1–0.5 mol %), **L1** (0.2–1 mol %), *t*BuOH (1.5 mL), 120 °C, 5 h. Yield of isolated product, average of two runs. [b] 2-Aminoimidazole sulfate (1.1 mmol), K₃PO₄ (2.5 mmol) and DMF were used.

a Cu-catalyzed reaction of 3-aminoindazole, followed by arylation by the Pd-catalyzed method. In both cases, the reaction order was important. In the first case, only a trace amount of **3** was obtained when the Pd-catalyzed system was used as the second step. For the synthesis of **4**, the use of a Pd-




Scheme 2. Selective syntheses of diarylaminoazoles.

Table 3: Scope of the Cu-catalyzed N-arylation.^[a]



[a] Aryl halide (1 mmol), aminoazole (1.1 mmol), Cs_2CO_3 (1.5 mmol), CuI (10 mol%), **L5** (15 mol%), *t*BuOH (1.5 mL), 90–110 °C, 16 h. Yield of isolated product, average of two runs. [b] 0.5 mmol scale. [c] 2-Aminoimidazole sulfate (1.1 mmol), Cs_2CO_3 (2.5 mmol) were used.

catalyst for the first arylation of 3-amioindazole gave a mixture of mono- and diarylated products.^[19]

In summary, we have developed an orthogonal set of Pd- and Cu-catalyzed N-arylations of 2-aminobenzimidazoles and related aminoazoles. Selective N-arylation of the primary amino group of 2-aminobenzimidazoles was achieved by using Pd-catalyzed methods, while selective N-arylation of the azole nitrogen was achieved with Cu catalysis. These general protocols are compatible with a variety of aryl halides and give facile access to an array of both isomers of N-arylaminoazoles from common aminoazole precursors.

Received: June 15, 2012

Published online: September 11, 2012

Keywords: aminoazole · C-N coupling · copper · N-arylation · palladium

- [1] a) D. S. Surry, S. L. Buchwald, *Angew. Chem.* **2008**, *120*, 6438–6461; *Angew. Chem. Int. Ed.* **2008**, *47*, 6338–6361; b) J. F. Hartwig, *Nature* **2008**, *455*, 314–322.
[2] a) X. Huang, K. W. Anderson, D. Zim, L. Jiang, A. Klapars, S. L. Buchwald, *J. Am. Chem. Soc.* **2003**, *125*, 6653–6655; b) A. Shafir, P. A. Lichtor, S. L. Buchwald, *J. Am. Chem. Soc.* **2007**, *129*, 3490–3491; c) R. A. Altman, A. M. Hyde, X. Huang, S. L.

- Buchwald, *J. Am. Chem. Soc.* **2008**, *130*, 9613–9620; d) D. Maiti, S. L. Buchwald, *J. Am. Chem. Soc.* **2009**, *131*, 17423–17429.
[3] a) S. Ueda, M. Su, S. L. Buchwald, *Angew. Chem.* **2011**, *123*, 9106–9109; *Angew. Chem. Int. Ed.* **2011**, *50*, 8944–8947; b) S. Ueda, M. Su, S. L. Buchwald, *J. Am. Chem. Soc.* **2012**, *134*, 700–706.
[4] R. D. Carpenter, M. Andrei, E. Y. Lau, F. C. Lightstone, R. Liu, K. S. Lam, M. J. Kurth, *J. Med. Chem.* **2007**, *50*, 5863–5867.
[5] E. A. Peterson, P. S. Andrews, X. Be, A. A. Boezio, T. L. Bush, A. C. Cheng, J. R. Coats, A. E. Colletti, K. W. Copeland, M. DuPont, R. Graceffa, B. Grubinska, J.-C. Harmange, J. L. Kim, E. L. Mullady, P. Olivieri, L. B. Schenkel, M. K. Stanton, Y. Teffera, D. A. Whittington, T. Cai, D. S. La, *Bioorg. Med. Chem. Lett.* **2011**, *21*, 2064–2070.
[6] M. Zhong, M. Bui, S. Wang, S. Baskaran, D. A. Allen, R. A. Elling, W. M. Flanagan, A. D. Fung, E. J. Hanan, S. O. Harris, S. A. Heumann, U. Hoch, S. N. Ivy, J. W. Jacobs, S. Lam, H. Lee, R. S. McDowell, J. D. Oslob, H. E. Purkey, M. J. Romanowski, J. A. Silverman, B. T. Tangonan, P. Taverna, W. Yang, J. C. Yoburn, C. H. Yu, K. M. Zimmerman, T. O'Brien, W. Lew, *Bioorg. Med. Chem. Lett.* **2009**, *19*, 5158–5161.
[7] V. J. Cee, A. C. Cheng, K. Romero, S. Bellon, C. Mohr, D. A. Whittington, A. Bak, J. Bready, S. Caenepeel, A. Coxon, H. L. Deak, J. Fretland, Y. Gu, B. L. Hodous, X. Huang, J. L. Kim, J. Lin, A. M. Long, H. Nguyen, P. R. Olivieri, V. F. Patel, L. Wang, Y. Zhou, P. Hughes, S. Geuns-Meyer, *Bioorg. Med. Chem. Lett.* **2009**, *19*, 424–427.
[8] T. Varming, P. Christophersen, A. Møller, D. Peters, O. Axelsson, E. Ø. Nielsen, *Bioorg. Med. Chem. Lett.* **1996**, *6*, 245–248.
[9] N. J. Press, WO 2005070906A1, **2005**.
[10] Selected examples for the synthesis of N¹-substituted 2-amino-benzimidazoles: a) C. J. Paget, K. Kisner, R. L. Stone, D. C. DeLong, *J. Med. Chem.* **1969**, *12*, 1010–1015; b) Y.-Q. Wu, D. C. Limburg, D. E. Wilkinson, G. S. Hamilton, *J. Heterocycl. Chem.* **2003**, *40*, 191–193; c) G. Evindar, R. A. Batey, *Org. Lett.* **2003**, *5*, 133–136.
[11] Selected examples for the synthesis of C²-NH₂-substituted 2-aminobenzimidazoles: a) D. B. Murphy, *J. Org. Chem.* **1964**, *29*, 1613–1615; b) R. Iemura, T. Kawashima, T. Fukuda, K. Ito, G. Tsukamoto, *J. Med. Chem.* **1986**, *29*, 1178–1183; Fukuda, K. Ito, G. Tsukamoto, *J. Med. Chem.* **1986**, *29*, 1178–1183; c) X.-J. Wang, L. Zhang, Y. Xu, D. Krishnamurthy, C. H. Senanayake, *Tetrahedron Lett.* **2004**, *45*, 7167–7170; d) P. Lan, F. A. Romero, T. S. Malcolm, B. D. Stevens, D. Wodka, G. M. Makara, *Tetrahedron Lett.* **2008**, *49*, 1910–1914; e) X. Deng, H. McAllister, N. S. Mani, *J. Org. Chem.* **2009**, *74*, 5742–5745; f) Z.-K. Wan, E. F. Ousman, N. Papaioannou, E. Saiah, *Tetrahedron Lett.* **2011**, *52*, 4149–4152.
[12] a) A. Kiyomori, J.-F. Marcoux, S. L. Buchwald, *Tetrahedron Lett.* **1999**, *40*, 2657–2660; b) A. Klapars, J. C. Antilla, X. Huang, S. L. Buchwald, *J. Am. Chem. Soc.* **2001**, *123*, 7727–7729; c) J. C. Antilla, J. M. Baskin, T. E. Barder, S. L. Buchwald, *J. Org. Chem.* **2004**, *69*, 5578–5587; d) H. Zhang, Q. Cai, D. Ma, *J. Org. Chem.* **2005**, *70*, 5164–5173; e) L. Liu, M. Frohn, N. Xi, C. Dominguez, R. Hungate, P. J. Reider, *J. Org. Chem.* **2005**, *70*, 10135–10138; f) R. A. Altman, E. D. Koval, S. L. Buchwald, *J. Org. Chem.* **2007**, *72*, 6190–6199; g) L. Liang, Z. Li, X. Zhou, *Org. Lett.* **2009**, *11*, 3294–3297; h) F. Monnier, M. Taillefer, *Angew. Chem.* **2009**, *121*, 7088–7105; *Angew. Chem. Int. Ed.* **2009**, *48*, 6954–6971.
[13] a) K. W. Anderson, R. E. Tundel, T. Ikawa, R. A. Altman, S. L. Buchwald, *Angew. Chem.* **2006**, *118*, 6673–6677; *Angew. Chem. Int. Ed.* **2006**, *45*, 6523–6527. See also Ref. [3b].
[14] a) A. Da Settimo, G. Primofiore, F. Da Settimo, G. Pardi, F. Simorini, A. M. Marini, *J. Heterocycl. Chem.* **2002**, *39*, 1007–1011; b) K. Koizumi, K. Shimabara, A. Takemoto, S. Yamazaki, N. Yamauchi, H. Fujii, M. Kurosawa, T. Konakahara, N. Abe, *Heterocycles* **2009**, *79*, 319–324.

- [15] For Pd-catalyzed N-arylation of N¹-substituted 2-aminobenzimidazole, see; a) J. Yin, M. M. Zhao, M. A. Huffman, J. M. McNamara, *Org. Lett.* **2002**, *4*, 3481–3484; b) M. A. McGowan, J. L. Henderson, S. L. Buchwald, *Org. Lett.* **2012**, *14*, 1432–1435; c) H. Yamashita, O. Odai, H. Harada, M. Iwata, WO 2008136444A1, **2008**; d) A. P. Thomas, R. Wood, WO 2007031745A1, **2007**.
- [16] Although regioselectivity was not disclosed, a few examples of the Pd-catalyzed C²-NH₂ arylation of 2-aminobenzimidazole derivatives were reported; a) M. V. Chelliah, S. Chackalamannil, W. J. Greenlee, K. A. Eagen, Z. Guo, M. C. Clasby, Y. Xia, C. L. Jayne, M. Dwyer, K. M. Keertikar, T.-Y. Chan, L. Wang, WO 2011017296A1, **2011**; b) A. Coates, S. M. Cramp, H. J. Dyke, Y. Hu, T. D. Pallin, WO 2008117079A1, **2008**; c) M. G. Hummersone, S. Gomez, K. A. Menear, G. C. M. Smith, K. Malagu, H. M. E. Duggan, X.-L. F. Cockcroft, G. J. Hermann, WO 2007060404A1, **2007**.
- [17] a) P. J. Fagan, E. Hauptman, R. Shapiro, A. Casalnuovo, *J. Am. Chem. Soc.* **2000**, *122*, 5043–5051; b) J. C. Zhou, P. N. Confalone, H.-Y. Li, L. M. Oh, L. T. Rossano, C. G. Clark, C. A. Teleha, WO 2002008199A2, **2002**.
- [18] For the arylation of 2-aminoimidazole sulfate, the use of DMF as solvent was crucial to obtain the desired product **1h**.
- [19] See Supporting Information for details.